Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 49 publications
Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives.
Journal: Neurology and therapy
Published: July 26, 2023
Disease stability over five years in people with multiple sclerosis treated with cladribine tablets: a plain language summary.
Journal: Neurodegenerative disease management
Published: August 26, 2022
Relapses in people with multiple sclerosis treated with cladribine tablets followed for up to 5 years: a plain language summary.
Journal: Neurodegenerative disease management
Published: August 26, 2022
The effect of cladribine tablets in people with more active multiple sclerosis: a plain language summary.
Journal: Neurodegenerative disease management
Published: August 03, 2022
Determination of a clinically effective evobrutinib dose: Exposure-response analyses of a phase II relapsing multiple sclerosis study.
Journal: Clinical and translational science
Published: April 22, 2022
Side effects that occurred early in people with multiple sclerosis during the first year of treatment with cladribine tablets: a plain language summary.
Journal: Neurodegenerative disease management
Published: January 12, 2022
Pharmacodynamic biomarkers of long-term interferon beta-1a therapy in REFLEX and REFLEXION.
Journal: Journal of neuroimmunology
Published: May 24, 2021
Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial.
Journal: The Lancet. Respiratory medicine
Published: May 20, 2021
Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: May 10, 2021
Treatment-emergent adverse events occurring early in the treatment course of cladribine tablets in two phase 3 trials in multiple sclerosis.
Journal: Multiple sclerosis journal - experimental, translational and clinical
Published: January 12, 2021
Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis: post hoc analysis of subgroups with and without prior disease-modifying drug treatment.
Journal: Current medical research and opinion
Published: December 17, 2020
Last Updated: 09/26/2026